Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Single-site, Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum

NCT02199925 is registered in ClinicalTrials.gov with Isaac Melamed as lead sponsor.

NCT NCT02199925
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02199925 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Single-site, Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum
Lead sponsor
Isaac Melamed
Phase
Phase 4
Overall status
Unknown status
Start date
June 30, 2013
Completion date
July 31, 2015
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

asperger's disorder, autism, autistic disorder, pdd, pervasive developmental disorder